XFOR (X4 Pharmaceuticals) 1-Year Sharpe Ratio: 1.06 (As of Jul. 06, 2026)


XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $4.09
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals 1-Year Sharpe Ratio?

X4 Pharmaceuticals XFOR -1.09% 24 1-Year Sharpe Ratio is 1.06 as of Jul. 06, 2026. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 7 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-06), X4 Pharmaceuticals's 1-Year Sharpe Ratio is 1.06.

X4 Pharmaceuticals  (NAS:XFOR) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

X4 Pharmaceuticals 1-Year Sharpe Ratio Related Terms

XFOR vs CMPX, LRMR, PROK: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's 1-Year Sharpe Ratio falls into.


XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.06 mean?
X4 Pharmaceuticals (XFOR) has a 1-Year Sharpe Ratio of 1.06 as of Jul. 06, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' 1-Year Sharpe Ratio too high?
X4 Pharmaceuticals' current 1-Year Sharpe Ratio is 1.06. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' 1-Year Sharpe Ratio compare to CMPX and LRMR?
X4 Pharmaceuticals' 1-Year Sharpe Ratio of 1.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current 1-Year Sharpe Ratio is 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current 1-Year Sharpe Ratio of 1.06. The current 1-Year Sharpe Ratio is 1.06. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current 1-Year Sharpe Ratio is 1.06 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.09
Price